Department of Clinical and Toxicological Analysis, Federal University of Rio Grande do Norte, Natal, Brazil.
Molecular Biology Laboratory, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil.
PLoS Negl Trop Dis. 2024 Feb 1;18(2):e0011865. doi: 10.1371/journal.pntd.0011865. eCollection 2024 Feb.
Chagas cardiomyopathy (ChCM) is a severe form of Chagas disease and a major cause of cardiovascular morbidity and mortality. The dysregulation of the immune response leads to cardiac remodeling and functional disruptions, resulting in life-threatening complications. Conventional diagnostic methods have limitations, and therapeutic response evaluation is challenging. MicroRNAs (miRNAs), important regulators of gene expression, show potential as biomarkers for diagnosis and prognosis.
This review aims to summarize experimental findings on miRNA expression in ChCM and explore the potential of these miRNAs as biomarkers of Chagas disease.
The search was conducted in the US National Library of Medicine MEDLINE/PubMed public database using the terms "Chagas cardiomyopathy" OR "Chagas disease" AND "microRNA" OR "miRNA" OR "miR." Additionally, bioinformatics analysis was performed to investigate miRNA-target interactions and explore enrichment pathways of gene ontology biological processes and molecular functions.
The miR-21, miR-146b, miR-146a, and miR-155 consistently exhibited up-regulation, whereas miR-145 was down-regulated in ChCM. These specific miRNAs have been linked to fibrosis, immune response, and inflammatory processes in heart tissue. Moreover, the findings from various studies indicate that these miRNAs have the potential as biomarkers for the disease and could be targeted in therapeutic strategies for ChCM.
In this review, we point out miR-21, miR-146b, miR-146a, miR-155, and miR-145-5p role in the complex mechanisms of ChCM. These miRNAs have been shown as potential biomarkers for precise diagnosis, reliable prognostic evaluation, and effective treatment strategies in the ChCM.
恰加斯心肌病(Chagas cardiomyopathy,ChCM)是一种严重的恰加斯病形式,也是心血管发病率和死亡率的主要原因。免疫反应失调导致心脏重构和功能障碍,从而引发危及生命的并发症。传统的诊断方法存在局限性,治疗反应评估具有挑战性。微小 RNA(miRNA)作为基因表达的重要调控因子,具有作为 Chagas 病诊断和预后生物标志物的潜力。
本综述旨在总结 ChCM 中 miRNA 表达的实验发现,并探讨这些 miRNA 作为 Chagas 病生物标志物的潜力。
在美国国家医学图书馆 MEDLINE/PubMed 公共数据库中使用“恰加斯心肌病”或“恰加斯病”和“microRNA”或“miRNA”或“miR”等术语进行搜索。此外,还进行了生物信息学分析,以研究 miRNA-靶相互作用,并探索基因本体生物过程和分子功能的富集途径。
miR-21、miR-146b、miR-146a 和 miR-155 一致表现出上调,而 miR-145 在 ChCM 中下调。这些特定的 miRNA 与心脏组织中的纤维化、免疫反应和炎症过程有关。此外,来自不同研究的结果表明,这些 miRNA 具有作为疾病生物标志物的潜力,并且可以作为 ChCM 治疗策略的靶点。
在本综述中,我们指出了 miR-21、miR-146b、miR-146a、miR-155 和 miR-145-5p 在 ChCM 的复杂机制中的作用。这些 miRNA 已被证明是 ChCM 精确诊断、可靠预后评估和有效治疗策略的潜在生物标志物。